Psoriasis pathophysiology: Current concepts of pathogenesis

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Krueger, J G ^a   Bowcock, A ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; EFALIZUMAB; TUMOR NECROSIS FACTOR;

AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CELL HYPERPLASIA; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONFERENCE PAPER; DRUG TARGETING; GENETICS; GENOMICS; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; T LYMPHOCYTE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOCYTES; PSORIASIS;

EID: 14244258610     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.031120     Document Type: Conference Paper

References (52)

1. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
2. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dematol 2003;49:S87-S97.
3. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, et al. Efalizumab Study Group. Efalizumab far patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80.
4. Victor FC, Gottlieb AB. TNF-alpha and apaptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002;1:264-75.
5. Rahman P, Elder JT. Genetic epidemiology of psoriasis and osoriatic arthritis. Ann Rheum Dis 2005;64(suppl II):ii37-9.
6. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004;13:R43-R55.
7. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003;35:349-56.
8. Shenolikar S, Weinman EJ. NHERF: targeting and trafficking membrane proteins. Am J Physiol Renal Physiol 2001;280:F389-F395.
9. Voltz JW, Weinman EJ, Shenolikar S. Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene 2001;20:6309-14.
10. Weinman EJ. New functions for the NHERF family of proteins. J Clin invest 2001;108:185-6.
11. Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, Miyazaki M, et al. Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J Immunol 2002;168:541-4.
12. Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Cantone K, et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 2002;79:305-14.
13. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Not Genet 2002;32:666-9.
14. Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003;35:341-8.
15. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-5.
16. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phospnoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15:5256-67.
17. Karason A, Gudjonsson JE, Upmanyu R, Antonsdottir AA, Hauksson VB, Runasdottir EH, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence far imprinting. Am J Hum Genet 2003;72:125-31.
18. Samuelsson L, Enlund F, Torinsson A, Yhr M, Inerot A, Enerback C, et al. A genome-wide search far genes predisposing to familial psoriasis by using a stratification approach. Hum Genet 1999;105:523-9.
19. Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L, et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003;73:677-81.
20. Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl R. Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Not Genet 2003;33:25-32.
21. Sakaguchi N, Takahashi T, Hato H, Nomura T, Tagami T, Yamazaki S, et al. Altered thymic T-cell selection due to a mutation or the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003;426:454-60.
22. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
23. Krueger JG. The immunologic basis far the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
24. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeto7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-47.
25. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
26. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM, et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000;165:4076-85.
27. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-81.
28. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-61.
29. McGregor JM, Barker JN, Ross EL, MacDanald DM. Epidermal dendritic cells in psoriasis passess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins. J Am Acad Dermotol 1992;27:383-8,
30. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 1993;151:6535-45.
31. Deguchi M, Aiba S, Ohtoni H, Nagura H, Tagami H. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and grafr-versus-host disease. Arch Dermatol Res 2002;294:297-302.
32. Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446-53.
33. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
34. Koga T, Duan H, Urabe K, Furue M. In situ localization of CD83-pasitive dendritic cells in psoriatic lesions. Dermatology 2002;204:100-3.
35. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94:202-9.
36. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:1096-102.
37. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
38. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong WH, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleatide array. Physiol Genomics 2003;13:69-78.
39. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30.
40. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-95.
41. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efolizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
42. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829-35.
43. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al; Etanercept Psoriasis Study Group. Etonercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
44. Pine R. Convergence of TNFalpha and IFN gamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element. Nucleic Acids Res 1997;25:4346-54.
45. Buchler T, Hajek R, Bourkova L, Kovarova L, Musilova R, Bulikova A, et al. Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine 2003;21:877-82.
46. Kopp T, Kieffer JD, Rot A, Strommer S, Stingl G, Kupper TS. Inflammatory skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities of p40. J Invest Dermatol 2001;117:618-26.
47. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol 2003;170:5438-44.
48. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8.
49. Villodsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112:1571-80.
50. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6.
51. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003;127:178-86.
52. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, et al. IL-12 synergizes with IL-18 or IL-1 beta for IFN-gamma production from human T cells. Int Immunol 2000;12:151-16.